Sets the stage for a new, improved paradigm in drug discovery

Despite spending more than $135 billion annually on R&D, the pharmaceutical industry faces an innovation crisis. Given the complexities and the expense of R&D, this book argues that we can accomplish much more-with greater efficiency and less cost-when private and public sectors collaborate, each focusing on their core strengths.

Collaborative Innovation in Drug Discovery focuses on the early stage of drug discovery, the most critical barrier to delivering a steady flow of viable drug candidates into the pipeline. The book assesses the current state of drug discovery in the pharmaceutical industry, government, non-profit, and academia, identifying the areas where each sector excels and areas where gaps exist. Next, the authors explore ways these sectors can establish mutually beneficial partnerships in order to discover, develop, and bring to market improved, safer drugs to treat human diseases. Topics include:

• Status of healthcare and unmet medical needs
• Biomedical research environment, drug discovery efforts, and market risks in industry and academia
• NIH Roadmap and EU-OpenScreen initiatives
• Trends in academia-pharmaceutical partnerships, including case studies
• Drug repositioning, open source partnerships, and challenges and practices for conducting clinical trials

Editor Rathnam Chaguturu has assembled a panel of expert authors from around the world, representing all the sectors involved in drug discovery. Their contributions are not only based on a thorough review of the current literature, but also their own first-hand experience of what works and what doesn't.

Collaborative Innovation in Drug Discovery offers pharmaceutical scientists and managers working in both private and public sectors a new, more productive road map to discover drugs that the world needs.